Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class used to relieve pain, inflammation, swelling, stiffness, and joint pain associated with conditions such as osteoarthritis and rheumatoid arthritis. It works primarily by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which decreases the synthesis of prostaglandins—key mediators of pain and inflammation. Piroxicam also inhibits leukocyte migration to sites of inflammation and prevents thromboxane A2 formation by platelets. Its long half-life allows for once-daily dosing. Originally patented in 1968 by Pfizer and approved for medical use in 1979, it is now available as a generic medication under various brand names worldwide[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piroxicam.